scholarly journals Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR

2001 ◽  
Vol 171 (1) ◽  
pp. R1-R4 ◽  
Author(s):  
SK Peirce ◽  
WY Chen ◽  
WY Chen
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Normal Breast ◽  
Breast Cancer Cell Lines ◽  
Human Tissues ◽  
Normal Human

Human prolactin (hPRL) has been reported to be involved in breast and prostate cancer development. The hPRL receptor (hPRLR) is expressed in a wide variety of tissues in at least three isoforms. In this study, a one-step real time reverse transcription PCR technique was used to determine relative expression levels of hPRLR mRNA in eleven human breast cancer cell lines, HeLa cells, three prostate cancer cell lines and nine normal human tissues. The housekeeping gene beta-actin was used for internal normalization. We demonstrate that hPRLR mRNA is up-regulated in six of the eleven breast cancer cell lines tested when compared with normal breast tissue. Of the cancer cell lines tested, we found that T-47D cells have the highest level of hPRLR mRNA, followed by MDA-MB-134, BT-483, BT-474, MCF-7 and MDA-MB-453 cells. In two breast cancer cell lines (MDA-MB-468 and BT-549), the hPRLR levels were found to be comparable to that of normal breast tissue. Three breast cancer cell lines (MDA-MB-436, MDA-MB-157 and MDA-MB-231) expressed hPRLR mRNA at levels lower than that of normal tissue. In contrast, in all three commonly used prostate cancer cell lines (LNCaP, PC-3 and DU 145), the levels of hPRLR mRNA were found to be down-regulated relative to that of normal prostate tissue. Of nine normal human tissues tested, we found that the uterus and the breast have the highest levels of hPRLR mRNA, followed by the kidney, the liver, the prostate and the ovary. The levels of hPRLR mRNA were the lowest among the trachea, the brain and the lung.

scholarly journals Anticancer, Antibacterial, and Phytochemicals Derived From Extract of Aerva javanica (Burm.f.) Juss. ex Schult. Grown Naturally in Saudi Arabia

2019 ◽  
Vol 12 ◽  
pp. 194008291986426 ◽  
Author(s):  
Mohammed Al-Shehri ◽  
Mahmoud Moustafa
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Cancer Cells ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Hot Water ◽  
Breast Cancer Cell Lines ◽  
Moderate Activity

Aerva javanica (Burm.f.) Juss. ex Schult. (Amaranthaceae family) has many pharmaceutical properties. This study aimed to determine the anticancerous effect of A. javanica methanol extract (AJME) on breast cancer cell lines and prostate cancer cell lines. The antibacterial potency of A. javanica solvent extracts was tested against Micrococcus luteus, Staphylococcus aureus, Pseudomonas aeruginosa, and Shigella flexneri. A screening of five concentrations of A. javanica was done on prostate and breast cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. The results showed that AJME had various levels of cytotoxicity toward both cancer cell lines. A significant decrease in the rate of cancer cells was associated with a higher concentration of the plant extract. The half maximal inhibitory concentration IC50 value was 4.50 μg/ml for the breast cancer cells and 14.51 μg/ml for the prostate cancer cells. The dried and fresh solvent extracts made with methanol and chloroform demonstrated maximum potency against all the tested pathogenic microbes. The petroleum ether and acetone extracts showed moderate activity, while the diethyl ether and hot water extracts had the lowest antibacterial activity. The gas chromatography-mass spectroscopy analysis showed that AJME had various chemical compounds that have many biological benefits. In conclusion, A. javanica is a promising candidate as a natural herb to treat cancers, more so in breast cancer than in prostate cancer, and it has potential as an antimicrobial agent against multidrug-resistant microbes.

scholarly journals Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines

2008 ◽  
Vol 18 (5) ◽  
pp. 791-801 ◽  
Author(s):  
Y.-J. Shann ◽  
C. Cheng ◽  
C.-H. Chiao ◽  
D.-T. Chen ◽  
P.-H. Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Human Tissues ◽  
Genome Wide

scholarly journals Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

2014 ◽  
Vol 5 (2) ◽  
pp. 61-71 ◽  
Author(s):  
Dong Gui Hu ◽  
Theresa E. Hickey ◽  
Connie Irvine ◽  
Dhilushi Dodampege Wijayakumara ◽  
Lu Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Splice Variant ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Human Tissues ◽  
Androgen Receptor Splice Variant

Cytotoxic activity and anti-cancer potential of Ontario grown onion extracts against breast cancer cell lines

2018 ◽  
Vol 8 (3) ◽  
pp. 159 ◽  
Author(s):  
Meghan Fragis ◽  
Abdulmonem I. Murayyan ◽  
Suresh Neethirajan
Keyword(s):  
Breast Cancer ◽  
Cytotoxic Activity ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Cytotoxic Activities ◽  
Cancer Line ◽  
Mcf 7

Background: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among Canadian women. Cancer management through changes in lifestyle, such as increased intake of foods rich in dietary flavonoids, have been shown to decrease the risk associated with breast, liver, colorectal, and upper-digestive cancers in epidemiologic studies. Onions are high in flavonoid content and one of the most common vegetables. Additionally, onions are used in most Canadian cuisines.Methods: We investigated the effect of five prominent Ontario grown onion (Stanley, Ruby Ring, LaSalle, Fortress, and Safrane) extracts on two subtypes of breast cancer cell lines: a triple negative breast cancer line MDA-MB-231 and an ER+ breast cancer line MCF-7.Results: These onion extracts elicited strong anti-proliferative, anti-migratory, and cytotoxic activities on both the cancer cell lines. Flavonoids present in these onion extracts induced apoptosis, cell cycle arrest in the G2/M phase, and a reduction in mitochondrial membrane potential at dose-dependent concentrations. Onion extracts were more effective against MDA-MB-231 compared to the MCF-7 cell line. Conclusion: In this study, we investigated the extracts synthesized from Ontario-grown onion varieties in inducing anti-migratory, cytostatic, and cytotoxic activities in two sub-types of human breast cancer cell lines. Anti-tumor activity of these extracts depends upon the varietal and can be formulated into nutraceuticals and functional foods for the wellbeing of cancer patients. Overall, the results suggest that onion extracts are a good source of flavonoids with anti-cancerous properties.Keywords: onion extracts; flavonoids; anti-proliferative; breast cancer; cytotoxic activity

ANTITUMOR EFFECT OF SUNITINIB AND BORTEZOMIB ON BREAST CANCER CELL LINE IN VITRO

2017 ◽  
Vol 63 (1) ◽  
pp. 141-145
Author(s):  
Yuliya Khochenkova ◽  
Eliso Solomko ◽  
Oksana Ryabaya ◽  
Yevgeniya Stepanova ◽  
Dmitriy Khochenkov
Keyword(s):  
Breast Cancer ◽  
Cell Line ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Antitumor Effect ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Actual Problem

The discovery for effective combinations of anticancer drugs for treatment for breast cancer is the actual problem in the experimental chemotherapy. In this paper we conducted a study of antitumor effect of the combination of sunitinib and bortezomib against MDA-MB-231 and SKBR-3 breast cancer cell lines in vitro. We found that bortezomib in non-toxic concentrations can potentiate the antitumor activity of sunitinib. MDA-MB-231 cell line has showed great sensitivity to the combination of bortezomib and sunitinib in vitro. Bortezomib and sunitinib caused reduced expression of receptor tyrosine kinases VEGFR1, VEGFR2, PDGFRa, PDGFRß and c-Kit on HER2- and HER2+ breast cancer cell lines

Sign in / Sign up

Export Citation Format

Share Document